Redhill Biopharma Ltd. (NASDAQ:RDHL) had its price objective decreased by equities research analysts at Roth Capital from $27.00 to $20.00 in a research report issued on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective points to a potential upside of 288.35% from the stock’s previous close.

Several other brokerages also recently commented on RDHL. Zacks Investment Research upgraded Redhill Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, September 27th. HC Wainwright reiterated a “buy” rating and set a $36.00 target price (up from $33.00) on shares of Redhill Biopharma in a research note on Wednesday, October 4th. Seaport Global Securities initiated coverage on Redhill Biopharma in a research note on Friday, October 6th. They set a “buy” rating and a $19.00 target price for the company. Finally, UBS AG initiated coverage on Redhill Biopharma in a research note on Wednesday, September 13th. They set a “reduce” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $21.95.

Redhill Biopharma (NASDAQ:RDHL) opened at $5.15 on Tuesday. Redhill Biopharma has a one year low of $5.09 and a one year high of $12.09.

COPYRIGHT VIOLATION NOTICE: “Redhill Biopharma Ltd. (RDHL) Price Target Lowered to $20.00 at Roth Capital” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/14/redhill-biopharma-ltd-rdhl-price-target-lowered-to-20-00-at-roth-capital.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new stake in Redhill Biopharma in the 1st quarter valued at $101,000. Oppenheimer & Co. Inc. boosted its stake in Redhill Biopharma by 10.8% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock valued at $220,000 after purchasing an additional 2,500 shares during the period. Family Management Corp boosted its stake in Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock valued at $222,000 after purchasing an additional 8,750 shares during the period. D.A. Davidson & CO. boosted its stake in Redhill Biopharma by 10.0% in the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 4,000 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Redhill Biopharma by 144.1% in the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 36,600 shares during the period. Institutional investors and hedge funds own 10.74% of the company’s stock.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.